The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells

Neuro-Oncology

Volumn 16, Issue 1, 2014, Pages 29-37

  Kahn, Jenna ^a,b   Hayman, Thomas J ^a,c   Jamal, Muhammad ^a   Rath, Barbara H ^a   Kramp, Tamalee ^a   Camphausen, Kevin ^a   Tofilon, Philip J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

AZD2014; glioblastoma; mTOR; orthotopic xenograft; Radiation; tumor stem cell

Indexed keywords

AZD 2014; DOUBLE STRANDED DNA; GAMMA-H2AX PROTEIN, MOUSE; HISTONE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; RADIOSENSITIZING AGENT; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA STEM LIKE CELL; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RADIOSENSITIVITY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRAIN NEOPLASMS; CANCER STEM CELL; CELL CYCLE; CELL PROLIFERATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NUDE MOUSE; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HISTONES; HUMANS; MICE; MICE, NUDE; MORPHOLINES; MULTIPROTEIN COMPLEXES; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RADIATION-SENSITIZING AGENTS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; X-RAY THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891513783     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not139     Document Type: Article

References (44)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996
2. Kumaraswamy S, Chinnaiyan P, Shankavaram UT, Lu X, Camphausen K, Tofilon PJ. Radiation-induced gene translation profiles reveal tumor type and cancer-specific components. Cancer Res. 2008;68(10): 3819-3826
3. Lu X, de la Pena L, Barker C, Camphausen K, Tofilon PJ. Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res. 2006;66(2):1052-1061
4. Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ. Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res. 2012;72(9):2362-2372
5. Laplante M, Sabatini DM.mTORsignaling in growthcontrolanddisease. Cell. 2012;149(2):274-293
6. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell. 2009;136(4): 731-745
7. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70(1):288-298
8. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22
9. Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: Lessons learned from bench to bedside. Neuro Oncol. 2010;12(8): 882-889
10. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22(10):1926-1933
11. Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 1998;58(22):5002-5008
12. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5(1):e8
13. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clinl Oncol. 2005;23(23):5294-5304
14. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3 K and mTOR signaling pathways in cancer: New data on targeted therapies. Curr Oncol Rep. 2012;14(2):129-138
15. Benjamin D, Colombi M, Moroni C, Hall MN.Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat Rev. Drug Discov. 2011; 10(11):868-880
16. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 2010;16(20):4914-4920
17. Choo AY, Blenis J. Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle. 2009;8(4): 567-572
18. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7(2):e38
19. Hsieh AC, Costa M, Zollo O, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010;17(3):249-261
20. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284(12):8023-8032
21. Yu K, Shi C, Toral-Barza L, et al. Beyond rapalog therapy: Preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010;70(2):621-631
22. Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ. Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity. Transl Oncol. 2013;6(3):355-362
23. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012; 485(7396):55-61
24. Banerji U, Dean EJ, Gonzalez M, et al. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. J Clin Oncol. 2012;30:(suppl):abstr 3004
25. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res. 2009;15(16):5145-5153
26. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: Role of autophagic cell death. J Natl Cancer Inst. 2007;99(18):1410-1414
27. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4(5):440-452
28. Mccord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res: MCR. 2009;7(4):489-497
29. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401
30. Jamal M, Rath BH, Williams ES, Camphausen K, Tofilon PJ. Microenvironmental regulation of glioblastoma radioresponse. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2010;16(24):6049-6059
31. Hall PE, Lathia JD, Caldwell MA, ffrench-Constant C. Laminin enhances the growth of human neural stem cells in defined culture media. BMC Neurosci. 2008;9:71
32. Xu B, Kim ST, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Molecular and Cellular Biology. 2001;21(10):3445-3450
33. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393): 1497-1501
34. Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia. 2012;14(2): 150-158
35. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011-7021
36. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120(6):747-759
37. Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006;5(5):1183-1189
38. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24(1):200-216
39. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cel Biol. 2002; 22(4):1049-1059
40. Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nature Reviews Cancer. 2008;8(12):957-967
41. Banath JP, Macphail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiatedcervical cancercell lines.CancerRes.2004;64(19):7144-7149
42. Lobrich M, Shibata A, Beucher A, et al. gammaH2AX foci analysis for monitoring DNA double-strand break repair: Strengths, limitations and optimization. Cell Cycle. 2010;9(4):662-669
43. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9): 4010-4015
44. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391-403